1. Home
  2. ESNT vs CINGW Comparison

ESNT vs CINGW Comparison

Compare ESNT & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESNT
  • CINGW
  • Stock Information
  • Founded
  • ESNT 2008
  • CINGW N/A
  • Country
  • ESNT Bermuda
  • CINGW United States
  • Employees
  • ESNT N/A
  • CINGW 13
  • Industry
  • ESNT Property-Casualty Insurers
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • ESNT Finance
  • CINGW Health Care
  • Exchange
  • ESNT Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • ESNT N/A
  • CINGW N/A
  • IPO Year
  • ESNT 2013
  • CINGW 2021
  • Fundamental
  • Price
  • ESNT $58.43
  • CINGW $0.03
  • Analyst Decision
  • ESNT Buy
  • CINGW
  • Analyst Count
  • ESNT 7
  • CINGW 0
  • Target Price
  • ESNT $61.71
  • CINGW N/A
  • AVG Volume (30 Days)
  • ESNT 619.4K
  • CINGW N/A
  • Earning Date
  • ESNT 05-09-2025
  • CINGW N/A
  • Dividend Yield
  • ESNT 2.10%
  • CINGW N/A
  • EPS Growth
  • ESNT 5.38
  • CINGW N/A
  • EPS
  • ESNT 6.85
  • CINGW N/A
  • Revenue
  • ESNT $1,242,904,000.00
  • CINGW N/A
  • Revenue This Year
  • ESNT $3.71
  • CINGW N/A
  • Revenue Next Year
  • ESNT $4.58
  • CINGW N/A
  • P/E Ratio
  • ESNT $8.60
  • CINGW N/A
  • Revenue Growth
  • ESNT 12.00
  • CINGW N/A
  • 52 Week Low
  • ESNT $51.61
  • CINGW N/A
  • 52 Week High
  • ESNT $65.33
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • ESNT 62.04
  • CINGW N/A
  • Support Level
  • ESNT $57.88
  • CINGW N/A
  • Resistance Level
  • ESNT $58.91
  • CINGW N/A
  • Average True Range (ATR)
  • ESNT 1.12
  • CINGW 0.00
  • MACD
  • ESNT 0.33
  • CINGW 0.00
  • Stochastic Oscillator
  • ESNT 72.83
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: